Cardiome Pharma Corp. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported revenue was $5,754,000 against $5,911,000 a year ago. Operating loss was $6,385,000 against $4,501,000 a year ago. Loss before income taxes was $8,524,000 against $7,420,000 a year ago. Net loss was $8,512,000 against $7,514,000 a year ago. Loss per common share - diluted was $0.26 against $0.37 a year ago. Net cash used in operating activities was $7,260,000 against $1,635,000 a year ago. Purchase of property and equipment of $5,000. Purchase of intangible assets was $1,000 against $5,596,000 a year ago.

For the six months, the company reported revenue was $10,953,000 against $13,001,000 a year ago. Operating loss was $11,877,000 against $5,632,000 a year ago. Loss before income taxes was $14,814,000 against $8,611,000 a year ago. Net loss was $14,845,000 against $8,748,000 a year ago. Loss per common share - diluted was $0.46 against $0.46 a year ago. Net cash used in operating activities was $14,104,000 against $6,851,000 a year ago. Purchase of property and equipment was $5,000 against $9,000 a year ago. Purchase of intangible assets was $13,000 against $5,611,000 a year ago.

The company expects meaningful revenues to begin in 2018.